Difference between revisions of "Part:BBa K2382007"

(References)
(Usage and Biology)
Line 14: Line 14:
  
 
===Usage and Biology===
 
===Usage and Biology===
 +
And we add a start coden (ATG)
 +
This is the single chain variable fragment (scFv) of an antibody that have ability of binding
 +
aflatoxin. This part basically shares the same sequence with BBa_K2382011, except for a start
 +
codon ATG at the beginning.
 +
 
Since bacteria can’t produce the whole antibody, we decide to use scFv to
 
Since bacteria can’t produce the whole antibody, we decide to use scFv to
replace it. It contains two polypeptide chains linked by a linker. And we add a start coden (ATG)
+
replace it. It contains two polypeptide chains linked by a linker.
  
 
===Characterization of the Anti-aflatoxin scFv (with start coden)===
 
===Characterization of the Anti-aflatoxin scFv (with start coden)===

Revision as of 03:48, 30 October 2017

Anti-aflatoxin scFv (with start coden)


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 342
    Illegal SapI.rc site found at 255


Usage and Biology

And we add a start coden (ATG) This is the single chain variable fragment (scFv) of an antibody that have ability of binding aflatoxin. This part basically shares the same sequence with BBa_K2382011, except for a start codon ATG at the beginning.

Since bacteria can’t produce the whole antibody, we decide to use scFv to replace it. It contains two polypeptide chains linked by a linker.

Characterization of the Anti-aflatoxin scFv (with start coden)

References

(1) Li, X., et al., Molecular characterization of monoclonal antibodies against aflatoxins: a possible explanation for the highest sensitivity. Anal Chem, 2012. 84(12): p. 5229-35.

(2) Chen, X., Zaro, J. L., & Shen, W. (2013). Fusion protein linkers: Property, design and functionality. Advanced Drug Delivery Reviews, 65(10), 1357-1369. doi:10.1016/j.addr.2012.09.039